DOW JONES25,766.64-1190.95 -4.42%
S&P 5002,978.76-137.63 -4.42%
NASDAQ8,566.48-414.30 -4.61%

Adamis Pharmaceuticals Sees Prelim. Q4 Product Sales $16.3M, FY19 Product Sales $54.6M

Preliminary Unaudited Fourth Quarter and Full-Year 2019 Product Sales for GOCOVRI GOCOVRI product sales for the full year 2019 are anticipated to be approximately $54.6 million compared to $34.0 million for the same

Benzinga · 01/08/2020 14:19

Preliminary Unaudited Fourth Quarter and Full-Year 2019 Product Sales for GOCOVRI

GOCOVRI product sales for the full year 2019 are anticipated to be approximately $54.6 million compared to $34.0 million for the same period in 2018, an increase of 60%. Product sales for 2019 were based on total prescriptions of approximately 25,780 compared to 15,500 in 2018. Adamas expects GOCOVRI product sales to be approximately $16.3 million for the fourth quarter 2019 compared to $13.9 million for the third quarter 2019, a sequential increase of 17%. Fourth quarter 2019 prescriptions were 7,160 compared to 6,640 prescriptions for the third quarter 2019. New patients started on GOCOVRI in the fourth quarter 2019 was 750 compared to 710 in the preceding quarter. Adamas had approximately $132.6 million of cash, cash equivalents, and available-for-sale securities at December 31, 2019. These preliminary results are based on management’s initial analysis of operations for the quarter ended December 31, 2019. Adamas expects to report its full financial results for the fourth quarter and fiscal year 2019 in February 2020.

-- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 --

-- Total prescriptions of approximately 7,160 for fourth quarter 2019 and approximately 25,780 for full year 2019 --